Professor Dr med. H. Wiendl

Name Prof. Prof. h.c. Heinz Wiendl, MD, * 07.05.1968, male    

Nationality German

Position Professor, Chair

Major clinical interests

  • Neuroinflammation, neuroimmunology
  • Neurooncology
  • Immune therapy

 

Major research interests

  • Neuroinflammation and neuroimmunology
  • Immuneregulation in MS and autoimmune nervous system disorders
  • Inflammatory mechanisms of neurodegenation
  • Immune mediated mechanisms of neurodegeneration
  • Immune cell trafficking into the CNS
  • Biomarkers and biosignatures (related to MS, immune therapy and its adverse effects)

 

Academic education

Nov 07, 1997 Approbation, Friedrich Alexander University, Erlangen-Nürnberg/Germany

1989-1996 Medicine, Universities of Erlangen-Nürnberg /Germany, Basel/Switzerland, Duke/North Carolina/USA

 

Scientific Degrees

2004 Habilitation treatise: „Immune regulatory role of the muscle: Implications for the immune pathogenesis of inflammatory myopathies“

1996 Conferring of a doctorate (MD)

 

Appointments

2013 Professor and Chair, Department of Neurology, University of Muenster, Germany

2010 Professor and Chair, Department of Inflammatory Diseases of the Nervous System and Neurooncology, University of Muenster, Germany

2005-2010 Professor of Neurology, Head of Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Department of Neurology, University of Wuerzburg)

2004 Head, junior research group for neuroimmunology, Interdisciplinary Centre for Clinical Research in Tuebingen, Germany

2000-2004 Clinical and research fellow, Hertie Institute for Brain Research, Department of Neurology, University of Tuebingen

1998-2000 Scholarship granted by the Deutsche Forschungsgemeinschaft (DFG), Max Planck-Institute for Neurobiology, department of neuroimmunology, Martinsried (Prof. H. Wekerle, MD; Prof. R. Hohlfeld, MD)

1997-1998 Research fellow, Institute of Anatomy and Neuro-Anatomy II of the University of Erlangen-Nuremberg

1996-1997 Member of the residency program, Department of Neurology of the University of Erlangen-Nuremberg

 

Calls, appointments, offers

  1. W3 professorship University of Regensburg (primo loco) 2017 (pending)
  2. NIH neuroimmunology branch leadership 2015 (not accepted)
  3. C3 professorship University of Wuerzburg, Germany (primo loco) 2004 (accepted)
  4. W3 professorship of the Schilling foundation (W3), Institute of Neuroimmunology, 2009 (not accepted)
  5. W3 professorship for neuroinflammation, University of Muenster (primo loco) 2009 (accepted)
  6. W3 professorship for neurology, Department of Neurology, Mainz (secundo loco)

 

Publications Neurology – examples from the last years

  1. Gerwien H*, Hermann S, Zhang X, Korpos E, Song J, Kopka K, Faust A, Wenning C, Gross CC, Honold L, Melzer M, Opdenakker G, Wiendl H, Schäfers M*, Sorokin L.* Imaging Matrix Metalloproteinase Activity in Multiple Sclerosis as a Specific Marker of Leukocyte Penetration of the Blood-Brain Barrier. Sci Transl Med. 2016;8(364):364ra152.
  2. Klotz L, Kuzmanov I, Hucke S, Gross CC, Posevitz V, Dreykluft A, Schulte-Mecklenbeck A, Janoschka C, Lindner M, Herold M, Schwab N, Ludwig-Portugall I, Kurts C, Meuth SG, Kuhlmann T, Wiendl H. B7-H1 shapes T-cell-mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity. Proc Natl Acad Sci U S A. 2016;113(41):E6182-E6191.
  3. Gross CC, Schulte-Mecklenbeck A, Rünzi A, Kuhlmann T, Posevitz-Fejfár A, Schwab N, Schneider-Hohendorf T, Herich S, Held K, Konjevi? M, Hartwig M, Dornmair K, Hohlfeld R, Ziemssen T, Klotz L, Meuth SG, Wiendl H. Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proc Natl Acad Sci U S A. 2016;113(21):E2973-82.
  4. Schneider-Hohendorf T, Mohan H, Bien CG, Breuer J, Becker A, Gorlich D, Kuhlmann T, Widman G, Herich S, Elpers C, Melzer N, Dornmair K, Kurlemann G, Wiendl H, Schwab N (2016) CD8(+) T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing. Nat Commun 7:11153
  5. Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M, Riester K, O’Neill G, Elkins J. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2015;373(15):1418-28.
  6. Schneider-Hohendorf T, Rossaint J, Mohan H, Böning D, Breuer J, Kuhlmann T, Gross CC, Flanagan K, Sorokin L, Vestweber D, Zarbock A, Schwab N, Wiendl H. VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of T(H)17 cells. J Exp Med. 2014;211:1833-46
  7. Breuer J, Schwab N, Schneider-Hohendorf T, Marziniak M, Mohan H, Bhatia U, Gross CC, Clausen BE, Weishaupt C, Luger TA, Meuth SG, Loser K, Wiendl H. Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Ann Neurol. 2014;75:739-58
  8. Bittner S*, Ruck T*, Schuhmann MK, Herrmann AM, Maati HMO, Bobak N, Göbel K, Langhauser F, Stegner D, Ehling P, Borsotto M, Pape H, Nieswandt B, Kleinschnitz C, Heurteaux C, Galla H, Budde T, Wiendl H*, Meuth SG*. Endothelial TWIK-related potassium channel-1 (TREK 1) regulates immune-cell trafficking into the CNS. Nat Med. 2013;19:1161-5 *equal contribution
  9. Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfar A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Gölz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. 2013;81:865-71
  10. Kleinschnitz C, Kraft P, Dreykluft A, Hagedorn I, Gobel K, Schuhmann MK, Langhauser F, Helluy X, Schwarz T, Bittner S, Mayer CT, Brede M, Varallyay C, Pham M, Bendszus M, Jakob P, Magnus T, Meuth SG, Iwakura Y, Zernecke A, Sparwasser T, Nieswandt B, Stoll G, Wiendl H. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. 2013;121:679-91

 

Since 1998 more than 380 peer reviewed publications (http://www.ncbi.nlm.nih.gov/pubmed/?term=Wiendl+H), e.g. Nature Medicine, Nature communications, Journal of Experimental Medicine, PNAS, New England Journal of Medicine, Blood, Annals of Neurology, BRAIN, Neurology, Nature Neuroscience, Immunity, 3 books (editor), several book chapters

*equal senior authorship+correspondence

 

Awards

2015 Sobek award for MS research of the German Society for Multiple Sclerosis (DMSG)

2009 Heinrich Pette award of the German Society for Neurology (DGN)

2004 Sobek award for MS research (young scientists’ award) of the DMSG

2003 Felix-Jerusalem award of the German Society for Muscular Diseases (DGM)

 

Special recognitions

2017 Honorary Professor, Sydney Medical School

2016- Member, International Advisory Board of the International Society of Neurosciences (ISNI)

2016- Member, Expert’s Committee on Neurosciences of the German Research Fundation (DFG)

2016- Member, ISNI

2016- Representative of the Academia, Board of directors of the University Hospital Muenster (UKM)

2016- Spokesperson, DFG funded transregional co-operative research centre (TR-CRC) Multiple Sclerosis“(Rhine-Main, Muenster, Munich) (evaluated 03/2016)

2016- Member, Expert Committee for cellular neurosciences at the DFG

2016- Representative of the academia, supervisory board of the UKM

2015- Member, commission „Perspectives in Neurology“ of the DGN

2013- Editorial board member, Neurotherapeutics

2014- Member, Academy of Education and Training, Medical Association for Westfalen-Lippe

2013- Executive board member, Felgenhauer Foundation for young Neuroscientists

2013- Scientific advisory board member, Foundation for Neuromedicine, Muenster

2013- Editorial Board Member, PLoS ONE

2013-2017  Dean for Research and Young Scientists, medical faculty Muenster

2012-2016 Co-Spokesperson, DFG-funded TR-CRC 128 “Multiple Sclerosis”

2012- Principal investigator and member of the steering committee, DFG-funded cluster of excellence “Cells in Motion” (CiM), Muenster

2012- Spokesperson for neuromedicine in Münster

2012-2014 Board member, Interdisciplinary Centre for Clinical Research (IZKF) Muenster

2011- Executive board member, German Society for Neurologists (BDN)

2009-2013 Spokesperson, BMBF-funded National German Competence Network of Multiple sclerosis (KKNMS)

2010- Member, Drug Commission of the German Medical Association

2008, 2014 Coordinator, therapeutic guidelines of the German Society for Neurology: myositis, myasthenia gravis

2008 Member, rviewers committee “Autoimmune Centers of Excellence” for the National Institutes of Health (NIH)

2007, 2011 Executive board member, DMSG

2007- Editorial board member, Journal of Neuroinflammation

2006- Member of the international editorial board, Journal of Clinical Practice

2004- Member, scientific advisory committee for the international conferences on HLA-G

2003- Member, scientific advisory committee of the DGM

2002- Member, medical council of the DMSG

2001, 2012, 2014 Member, Multiple Sclerosis Therapy Consensus Group (MSTCG)

 

Reviewer for scientific journals (examples)

Annals of Neurology, Annals of Clinical and Translational Neurology, Blood, Brain, Journal of Immunology, FASEB Journal, Human Immunology, International Journal of Cancer, JAMA, JAMA Neurology, Journal of Clinical Investigations, Journal of Experimental Medicine, Journal of Immunology, Journal of Neurochemistry, Journal of Neuroimmunology, Journal of Neuroinflammation, Journal of the Neurological Sciences, Lancet, Lancet Neurology, Multiple Sclerosis Journal, Multiple Sclerosis and Related Disorders, Nature Medicine, Neurology, Neurology: Neuroimmunology & Neuroinflammation; Neurotherapeutics, New England Journal of Medicine, Recent Patents on Inflammation & Allergy Drug Discovery, Trends in Immunology

 

Reviewer for institutions (examples)

Academy of Sciences Finland, Alexander von Humboldt-Stiftung, American Myositis Association, Association Française contre les Myopathies, Austrian Science Fund, “Autoimmune Centers of Excellence” for the National Institutes of Health (NIH), BONFOR – Forschungskommission der Medizinischen Fakultät Bonn, Canadian Institutes of Health Research (CIHRS), Deutsche Forschungsgemeinschaft (DFG), Deutsche Multiple-Sklerose-Gesellschaft (DMSG), Diabetes UK, Medical Research Council (MRC), Duchenne Parents Project (DPP), MS Research Australia (MSRA), Multiple Sclerosis Society UK (MSS), Stiftung Rheinland-Pfalz für Innovation, National Institutes of Health (NIH), Wellcome Trust United Kingdom, Wilhelm Sander Stiftung, Fondation pour la Recherche Médicale, Wissenschaftsrat

 

Member of editorial boards

Endocrine Metabolic Immune Disorders – Drug Targets, International Journal of Clinical Practice, Journal of Neuroinflammation, Neurotherapeutics, Recent Patents on Inflammation & Allergy Drug Discovery, PLOS ONE

 

Memberships

Commission „Perspectives of patient care in neurology“ of the German Society for Neurology (DGN); Academy of Education and Training of the Medical Association for “Westfalen-Lippe”; executive board of the Felgenhauer Foundation for young neuroscientists; scientific advisory board of the Foundation for Neuromedicine, Muenster; steering committee of the cluster of excellence “Cells in Motion” (CiM), Muenster (funded by the German Research Foundation (DFG)); Interdisciplinary Centre for Clinical Research (IZKF) Muenster; executive board of the German Society for Neurologists (BDN); drug commission of the German Medical Association; executive board of the German Society for Multiple Sclerosis (DMSG); scientific advisory committee for the International Conferences on HLA-G; scientific advisory committee of the German Society for Muscular Diseases (DGM); medical council of the German Society for Multiple Sclerosis (DMSG); Multiple Sclerosis Therapy Consensus Group (MSTCG)

 

PI/Co-ordination of clinical trials (examples)

? 30 phase I-IV trials, including IITs as principal investigator, member of several steering committees (e.g. IL17 program, IL2R blockade program)

 

Funding

The German Ministry of Education and Research (BMBF), the North-Rhine Westphalian Ministry of Education and Research, The German Research Foundation (DFG), the European Union (EU), the Program for “Innovative Medical Research” (IMF) Muenster, the Interdisciplinary Center for Clinical Research (IZKF) Muenster, The Hertie Foundation, The Else Kroener Fresenius Foundation, the RE Children’s Foundation, The Thyssen Foundation and industry; Ad personam: 14.5 Mio. €/last 5 years